← Anika Therapeutics, Inc.

Annual Trend FY 2016 FY 2017 FY 2018 FY 2019 FY 2020 FY 2021 FY 2022 FY 2023 FY 2024 FY 2025
Cash flows from operating activities:
Adjustments to reconcile net income to net cash provided by operating activities:
Net Income (Loss) Attributable to Parent $32.5m $31.8m $18.7m $27.2m ($24.0m) $4.1m ($14.9m) ($82.7m) ($56.4m) ($10.9m)
Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent — — — — — — — — ($8.8m) ($10.0m)
Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest — — — — — — — — — ($901k)
Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent — — — — — — — — ($47.6m) ($901k)
Depreciation and amortization $3.7m $4.3m $5.9m $6.0m $13.5m $6.5m $6.7m $6.4m $6.9m $5.4m
Depreciation $2.7m $3.3m $4.9m $5.0m $6.1m $6.5m $6.7m $6.4m $5.0m $5.4m
Amortization of Intangible Assets $1.1m $1.0m $1.0m $1.0m $7.4m $7.8m $7.8m $7.8m $700k $400k
Deferred Income Tax Expense (Benefit) ($65k) ($1.2m) ($1.8m) $794k ($3.5m) ($1.8m) ($5.3m) ($6.3m) $260k ($7k)
Share-based Payment Arrangement, Noncash Expense $3.4m $5.8m $11.0m $6.1m $5.4m $11.1m $14.3m $15.2m $13.1m $10.1m
Payment, Tax Withholding, Share-based Payment Arrangement — — $1.8m $293k $262k $486k $934k $2.2m $2.6m $1.6m
Share-based Payment Arrangement, Expense $3.4m $5.8m $11.0m $6.1m $5.4m $11.1m $14.3m $15.2m $12.2m $10.2m
Goodwill and Intangible Asset Impairment — — — — — — — $62.2m — —
Goodwill, Impairment Loss — — — — $42.5m $0 $0 — — —
Impairment of Intangible Assets, Finite-lived — — — $389k $2.4m $600k $0 $62.2m $2.5m —
Gain (Loss) on Disposition of Property Plant Equipment — ($150k) ($152k) ($927k) ($265k) ($993k) $0 ($1.9m) ($2.9m) $166k
Income Tax Expense (Benefit) $18.3m $14.4m $4.5m $8.9m ($4.6m) ($1.7m) ($3.9m) ($2.7m) $6.1m $672k
Changes in operating assets and liabilities:
Additional Financial Items
Increase (Decrease) in Accounts Receivable $6.2m ($2.7m) ($2.9m) $1.8m ($5.9m) $6.2m $5.6m $1.3m ($3.4m) ($408k)
Increase (Decrease) in Inventories $1.7m $6.5m $7.6m $5.6m $14.2m $6.6m $6.9m $11.4m $9.4m ($30k)
Increase (Decrease) in Accounts Payable ($5.1m) $3.9m ($1.7m) $767k $822k ($1.1m) $2.0m ($11k) ($2.5m) $42k
Proceeds from Stock Options Exercised $1.0m $314k $2.9m $22.2m $1.5m $1.1m $16k $23k $76k $0
Foreign Currency Transaction Gain (Loss), before Tax ($300k) $700k ($400k) — $300k ($400k) ($500k) $100k ($200k) ($400k)
Gain (Loss) on Investments — — $371k $25k ($13k) — — — — —
Goodwill $7.2m $8.2m $7.9m $7.7m $8.4m $7.8m $7.3m $7.6m $7.1m $8.1m
Inventory Write-down $654k $695k $4.4m $1.6m $5.5m $6.6m $5.3m $3.3m $44.7m $5.8m
Net Cash Provided by (Used in) Operating Activities $23.8m $40.8m $34.9m $37.0m $13.1m $8.4m $4.4m ($1.8m) $5.4m $11.2m
Cash flows from investing activities:
Payments to Acquire Property, Plant, and Equipment $14.0m $9.0m $4.7m $2.8m $1.6m $5.1m $7.5m $5.4m $7.7m $6.8m
Payments to Acquire Businesses, Net of Cash Acquired — — — — $94.6m $476k $0 $0 — —
Net Cash Provided by (Used in) Investing Activities ($6.8m) ($12.5m) ($50.3m) $39.7m ($71.3m) ($3.1m) ($7.5m) ($5.4m) ($8.3m) ($401k)
Cash flows from financing activities:
Proceeds from Issuance of Long-term Debt — — — — $50.0m $0 $0 — — —
Repayments of Long-term Debt — — — — $50.4m $0 $0 — — —
Payments for Repurchase of Common Stock $25.0m — $30.0m $30.0m $0 $0 — $5.0m $10.9m $9.5m
Net Cash Provided by (Used in) Financing Activities ($23.3m) $314k ($28.9m) ($8.1m) ($3.8m) ($6.8m) ($4.9m) ($6.3m) ($12.7m) ($10.6m)
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect ($138k) $349k $29k ($133k) ($61.6m) ($1.4m) ($8.1m) ($13.5m) ($15.7m) $322k
Supplemental disclosure of cash flow information:
Income Taxes Paid, Net $22.8m $15.1m $5.6m $9.3m $993k $1.2m $106k $3.1m $4.0m $1.1m

Data sourced from SEC EDGAR 10-K filings via EdgarTools. Amounts are shown in USD as reported in each fiscal year filing.